In 1929 the Council issued a preliminary report on Coramine-Ciba (pyridine-b-carboxylic acid diethylamide), postponing action to await further experimental and clinical evidence (The Journal, June 1, 1929, p. 1837). In 1937 the Council's office asked Ciba Pharmaceutical Products, Inc., whether or not it intended to resubmit the product with any accumulated evidence. The firm replied that it intended to accomplish a resubmission. The firm later (1938) requested postponement of the date of resubmission to await completion of studies in progress.
Meanwhile, in view of the fact that the patent was to expire with the close of 1939, the Upjohn Company asked the Council to coin a nonproprietary name for the substance, subsequently expressing its intention of submitting the product on its own account. The Council consulted Ciba Pharmaceutical Products, Inc., and agreement was reached on the name "Nikethamide" (pronounced "nik-eth'-amide"). The Council voted to recognize the term as the nonproprietary